C-KIT overexpression and mutation in nasopharyngeal carcinoma cell lines and reactivity of imatinib on these cell lines

Chinese Journal of Cancer

Volumn 29, Issue 2, 2010, Pages 131-135

  Huang, Pei Yu ^a   Hong, Ming Huang ^a   Zhang, Xing ^a   Mai, Hai Qiang ^a   Luo, Dong Hua ^a   Zhang, Li ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

C KIT; Gene mutation; Nasopharyngeal carcinoma; Proliferation inhibitory effect; Protein expression

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; GENOMIC DNA; IMATINIB; STEM CELL FACTOR RECEPTOR;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL SPECIFICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; GENE MUTATION; GENETIC ANALYSIS; GROWTH INHIBITION; HETEROZYGOTE; HOMOZYGOTE; IN VITRO STUDY; INTRON; MITOSIS INHIBITION; NASOPHARYNX CARCINOMA; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 79955822248     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.009.10411     Document Type: Article

References (19)

1. Huang PY, Wang B, Zhang X, et al. Expression and clinical significance of c-kit in nasopharyngeal carcinoma on tissue microarrary [J]. Chin Clin Oncol, 2009,14(2):97-101. [in Chinese].
2. Huang PY, Zhang L, Zhang X, et al. C-KIT mutation exists in nasopharyngeal carcinoma [J]. Chin Oncol, 2009,19 (4):266-269. [in Chinese].
3. Sheu LF, Young ZH, Lee WC, et al. STI571 sensitizes nasopharyngeal carcinoma cells to cisplatin: sustained activation of ERK with improved growth inhibition [J]. Int J Oncol, 2007, 30(2):403-411.
4. Bar-Sela G, Kuten A, Ben-Eliezer S, et al. Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach [J]. Mod Pathol, 2003, 16(10):1035-1040.
5. Bar-Sela G, Ben Arush MW, Sabo E, et al. Pediatric nasopharyngeal carcinoma: better prognosis and increased c-Kit expression as compared to adults [J]. Pediatr Blood Cancer, 2005, 45(3):291-297.
6. Sheu LF, Lee WC, Lee HS, et al. Co-expression of c-kit and stem cell factor in primary and metastatic nasopharyngeal carcinomas and nasopharyngeal epithelium [J]. J Pathol, 2005, 207(2):216-223.
7. Charfi S, Khabir A, Ayadi L, et al. Expression of c-kit in North African nasopharyngeal carcinomas: correlation with age and LMP1 [J]. Cancer Radiother, 2007, 11(5):247-251.
8. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34 [J]. Mod Pathol, 1998, 11(8):728-734.
9. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor [J]. J Clin Oncol, 2003, 21(23):4342-4349.
10. La Rosee P, Johnson K, O'Dwyer ME, et al. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia [J]. Exp Hematol, 2002, 30(7):729-737.
11. Merchant MS, Woo CW, Mackall CL, et al. Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity [J]. J Natl Cancer Inst, 2002, 94(22):1673-1679.
12. Krystal GW, Honsawek S, Litz J, et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth [J]. Clin Cancer Res, 2000, 6(8):3319-3326.
13. Attoub S, Rivat C, Rodrigues S, et al. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy [J]. Cancer Res, 2002, 62(17):4879-4883.
14. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet- derived growth factor receptors [J]. J Pharmacol Exp Ther, 2000, 295(1): 139-145.
15. Duffaud F, Le Cesne A. Imatinib in the treatment of solid tumours [J]. Targeted Oncol, 2009, 4(1):45-56.
16. Kemmer K, Corless CL, Fletcher JA, et al. KIT mutations are common in testicular seminomas [J]. Am J Pathol, 2004, 164(1):305-313.
17. Heinrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies [J]. J Clin Oncol, 2002, 20(6):1692-1703.
18. Sihto H, Sarlomo-Rikala M, Tynninen O, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors [J]. J Clin Oncol, 2005, 23(1):49-57.
19. Burger H, den Bakker MA, Kros JM, et al. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes [J]. Cancer Biol Ther, 2005, 4(11):1270-1274.